InvestSMART

ORDINARY FULLY PAID (ASX: OPT) - Announcements

DELISTED - Current share price for OPT : $0.013

ASX company news and announcements for ORDINARY FULLY PAID (OPT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ORDINARY FULLY PAID (OPT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ORDINARY FULLY PAID (OPT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ORDINARY FULLY PAID (OPT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Letter to Option Holders 30 Oct 2018 11:33AM $0.570 $0.013 fallen by 97.72%
$18 Opthea Provides Update on Key Opinion Leader Forum 29 Oct 2018 9:50AM $0.575 $0.013 fallen by 97.74%
$18 Notice of Annual General Meeting and Proxy Form 29 Oct 2018 9:39AM $0.575 $0.013 fallen by 97.74%
$18 Notice of Annual General Meeting and Proxy Form 26 Oct 2018 9:14AM $0.570 $0.013 fallen by 97.72%
$18 Opthea CEO Presentation of Trial Updates at OIS@AAO 2018 26 Oct 2018 8:45AM $0.570 $0.013 fallen by 97.72%
$18 Opthea Reports Positive Data from Ph1b DME Study of OPT-302 26 Oct 2018 8:41AM $0.570 $0.013 fallen by 97.72%
$18 Opthea To Present at the Ophthalmology Innovation Summit 24 Oct 2018 8:49AM $0.600 $0.013 fallen by 97.83%
$18 Appendix 3B 22 Oct 2018 9:12AM $0.600 $0.013 fallen by 97.83%
$18 Appendix 3B 15 Oct 2018 8:40AM $0.600 $0.013 fallen by 97.83%
$18 Appendix 3B 28 Sep 2018 8:42AM $0.585 $0.013 fallen by 97.78%
$18 Change in substantial holding 26 Sep 2018 9:01AM $0.585 $0.013 fallen by 97.78%
$18 Opthea to Host wAMD and DME Key Opinion Leader Forum 24 Sep 2018 8:36AM $0.605 $0.013 fallen by 97.85%
$18 Appendix 3B 20 Sep 2018 9:23AM $0.590 $0.013 fallen by 97.80%
$18 Opthea Doses First Patients in Australia for Phase 2a in DME 17 Sep 2018 8:35AM $0.630 $0.013 fallen by 97.94%
$18 Opthea presents Ph1/2a wAMD data at Retina Society Meeting 14 Sep 2018 8:33AM $0.585 $0.013 fallen by 97.78%
$18 Opthea Receives Positive Safety Review for Ph2b wAMD Trial 5 Sep 2018 8:36AM $0.625 $0.013 fallen by 97.92%
$18 Appendix 4G and Corporate Governance Statement 2018 28 Aug 2018 8:25AM $0.610 $0.013 fallen by 97.87%
$18 Opthea Appendix 4E and Annual Report 2018 28 Aug 2018 8:20AM $0.610 $0.013 fallen by 97.87%
$18 Appendix 3B 6 Aug 2018 10:17AM $0.540 $0.013 fallen by 97.59%
$18 Opthea Doses First Patient in Ph2a Trial for OPT-302 in DME 30 Jul 2018 9:30AM $0.555 $0.013 fallen by 97.66%
$18 Opthea Meets Primary Safety Objective in DME Phase 1b trial 26 Jul 2018 8:30AM $0.565 $0.013 fallen by 97.70%
$18 Opthea reaches mid-way in recruitment for Ph2b wAMD trial 2 Jul 2018 8:48AM n/a $0.013 n/a
$18 Appendix 3B 27 Jun 2018 8:26AM $0.515 $0.013 fallen by 97.48%
$18 Change in substantial holding 30 May 2018 5:41PM $0.430 $0.013 fallen by 96.98%
$18 Ceasing to be a substantial holder for ANP 11 May 2018 4:49PM $0.500 $0.013 fallen by 97.40%

626 - 650 of 733 results

Page 26 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.